CTOs on the Move

Aspen Neuroscience

www.aspenneuroscience.com

 
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kim Raineri
Chief Technology Officer Profile

Funding

Aspen Neuroscience raised $70M on 04/01/2020
Aspen Neuroscience raised $147.5M on 05/09/2022

Similar Companies

Triad Technologies

Triad Technologies, Llc is a Englewood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sangart

Sangart is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ceribell

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

Q32 Bio

Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.

Cerapedics

i-FACTOR Peptide Enhanced Bone Graft is a drug/device combination that creates a new category of bone graft technology. Take a moment to review our introduction to i-FACTOR, our Level-1 IDE study and comparative performance sections given below.